Arbutus Biopharma News

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a

Arbutus BiopharmaApr 18 00:00 ET

Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge

A Delaware District Court sided with Arbutus Biopharma Corporation (NASDAQ:ABUS) and Genevant Sciences in their ongoing patent infringement case against Moderna Inc (NASDAQ:MRNA) COVID-19 vaccine.The

BenzingaApr 4 14:32 ET

Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead

Moderna Inc (NASDAQ:MRNA) stock closed lower by 2.32% on Wednesday, as news around Arbutus Biopharma (NASDAQ:ABUS) impacted investor sentiment. Arbutus has received permission to pursue its patent inf

BenzingaApr 4 09:34 ET

Express News | JMP Securities Reiterates Market Outperform on Arbutus Biopharma, Maintains $4 Price Target

Moomoo 24/7Apr 4 08:49 ET

Unpleasant Surprises Could Be In Store For Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares

You may think that with a price-to-sales (or "P/S") ratio of 28.9x Arbutus Biopharma Corporation (NASDAQ:ABUS) is a stock to avoid completely, seeing as almost half of all the Biotechs companies in th

Simply Wall StApr 4 06:13 ET

Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Arbutus Biopharma (ABUS)

TipRanksApr 3 15:20 ET

Arbutus Biopharma Up Over 14%, on Pace for Largest Percent Increase Since December 2021 -- Data Talk

Arbutus Biopharma Corporation (ABUS) is currently at $2.88, up $0.36 or 14.29% --Would be highest close since Feb. 28, 2024, when it closed at $2.88 --On pace for largest percent increase since Dec.

Dow JonesApr 3 13:44 ET

Arbutus Biopharma Jumps After Patent Victory in Fight With Moderna

Seeking AlphaApr 3 12:27 ET

Is Arbutus Biopharma (NASDAQ:ABUS) In A Good Position To Deliver On Growth Plans?

Yahoo FinanceApr 1 12:44 ET

Arbutus to Participate in Two Upcoming Investor Conferences

WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a

Arbutus BiopharmaMar 8 00:00 ET

Analysts Offer Insights on Healthcare Companies: Arbutus Biopharma (ABUS), Twist Bioscience (TWST) and Catalent (CTLT)

TipRanksMar 5 01:23 ET

Arbutus Biopharma Corporation (NASDAQ:ABUS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Yahoo FinanceMar 3 07:38 ET

Analysts Just Made A Major Revision To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenue Forecasts

Yahoo FinanceMar 2 07:29 ET

Arbutus Biopharma Price Target Maintained With a $4.00/Share by Chardan Capital

Arbutus Biopharma Price Target Maintained With a $4.00/Share by Chardan Capital

Dow JonesMar 1 07:59 ET

Arbutus Biopharma Is Maintained at Buy by HC Wainwright & Co.

Arbutus Biopharma Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMar 1 07:32 ET

Express News | HC Wainwright & Co. Maintains Buy on Arbutus Biopharma, Lowers Price Target to $5

Moomoo 24/7Mar 1 07:22 ET

Arbutus Biopharma Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/01/2024 77.3% HC Wainwright & Co. $6 → $5 Maintains Buy 09/12/2023 112.77% HC Wainwright & Co. → $6 Rei

BenzingaMar 1 07:21 ET

Earnings Call Summary | Arbutus Biopharma(ABUS.US) Q4 2023 Earnings Conference

The following is a summary of the Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript:Financial Performance:Arbutus Biopharma ended 2023 with approximately $132 million of cash, cash

moomoo AIFeb 29 17:37 ET · Conference Call

Buy Rating Affirmed for Arbutus Biopharma on Strong Clinical Outlook and Litigation Prospects

TipRanksFeb 29 13:55 ET

Arbutus Biopharma Anticipates Key 2024 Milestones

TipRanksFeb 29 08:19 ET